Gyre Therapeutics Inc banner

Gyre Therapeutics Inc
NASDAQ:GYRE

Watchlist Manager
Gyre Therapeutics Inc Logo
Gyre Therapeutics Inc
NASDAQ:GYRE
Watchlist
Price: 8.5 USD 4.29% Market Closed
Market Cap: $772.6m

Relative Value

The Relative Value of one GYRE stock under the Base Case scenario is hidden USD. Compared to the current market price of 8.5 USD, Gyre Therapeutics Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GYRE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

GYRE Competitors Multiples
Gyre Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Gyre Therapeutics Inc
NASDAQ:GYRE
770.8m USD 7.1 114.3 49.1 58.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 643 258.8 -159 901.4 -194 171.3 -191 955.6
US
Abbvie Inc
NYSE:ABBV
403.4B USD 6.8 171.9 16.6 23.6
US
Astria Therapeutics Inc
NASDAQ:ATXS
326.4B USD 462 374.5 -2 631.9 -2 377 -2 377
US
Amgen Inc
NASDAQ:AMGN
205.6B USD 5.6 26.7 15.2 15.2
US
Gilead Sciences Inc
NASDAQ:GILD
182.9B USD 6.2 21.5 14.6 14.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.9B USD 10.3 31.3 24 25
US
Epizyme Inc
F:EPE
94.1B EUR 2 094 -534.3 -581.8 -566.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.4B USD 5.7 18.1 13.6 15.5
NL
argenx SE
XBRU:ARGX
43.5B EUR 14.3 33.7 57.9 59.5
AU
CSL Ltd
ASX:CSL
70.3B AUD 3.2 16.4 11.3 14.1
P/S Multiple
Revenue Growth P/S to Growth
US
Gyre Therapeutics Inc
NASDAQ:GYRE
Average P/S: 3 100 707.9
7.1
12%
0.6
FR
Pharnext SCA
OTC:PNEXF
33 643 258.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
10%
0.7
US
Astria Therapeutics Inc
NASDAQ:ATXS
462 374.5
N/A N/A
US
Amgen Inc
NASDAQ:AMGN
5.6
3%
1.9
US
Gilead Sciences Inc
NASDAQ:GILD
6.2
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.3
11%
0.9
US
E
Epizyme Inc
F:EPE
2 094
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
NL
argenx SE
XBRU:ARGX
14.3
49%
0.3
AU
CSL Ltd
ASX:CSL
3.2
4%
0.8
P/E Multiple
Earnings Growth PEG
US
Gyre Therapeutics Inc
NASDAQ:GYRE
Average P/E: 54.2
114.3
-33%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -159 901.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
171.9
89%
1.9
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 631.9 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
26.7
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
21.5
14%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.3
17%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -534.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.1
13%
1.4
NL
argenx SE
XBRU:ARGX
33.7
42%
0.8
AU
CSL Ltd
ASX:CSL
16.4
11%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Gyre Therapeutics Inc
NASDAQ:GYRE
Average EV/EBITDA: 25.3
49.1
-63%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 171.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.6
14%
1.2
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 377 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.2
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
18%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
15%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581.8 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
23%
0.6
NL
argenx SE
XBRU:ARGX
57.9
810%
0.1
AU
CSL Ltd
ASX:CSL
11.3
8%
1.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Gyre Therapeutics Inc
NASDAQ:GYRE
Average EV/EBIT: 28.2
58.5
-7%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -191 955.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.6
30%
0.8
US
Astria Therapeutics Inc
NASDAQ:ATXS
Negative Multiple: -2 377 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
15.2
2%
7.6
US
Gilead Sciences Inc
NASDAQ:GILD
14.6
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -566.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
21%
0.7
NL
argenx SE
XBRU:ARGX
59.5
N/A N/A
AU
CSL Ltd
ASX:CSL
14.1
11%
1.3